Fibromyalgia research in 2026 is moving faster than it has in years. A new FDA-approved medicine reached pharmacies in late 2025, a prescription therapy app has strong trial results, and scientists are learning more about nerves, the immune system, and how the brain handles pain. None of this is a cure, but it does mean more options and a clearer picture of what fibromyalgia is.
Below, I walk through the biggest developments, what each one means for you today, and where caution is still needed. I only included items I could confirm with a dated, trusted source.
Fibromyalgia Research 2026: The Quick Overview
| Development | Where it stands |
|---|---|
| Tonmya (cyclobenzaprine under the tongue) | FDA-approved Aug 2025; in U.S. pharmacies since Nov 2025 |
| Stanza digital therapy app | FDA-authorized 2023; by prescription in some states |
| Small fiber nerve findings | Research finding; not a routine test for everyone |
| Antibody studies | Early lab research in mice |
| Nociplastic pain framework | Widely used way to describe fibromyalgia pain |
| New drug ideas (metformin and others) | Animal studies and early trials |
| Low-dose naltrexone | Off-label; two larger trials found no clear benefit |
1. Tonmya: The First New Fibromyalgia Medicine in Over 15 Years
What it is: On August 15, 2025, the FDA approved Tonmya (cyclobenzaprine HCl sublingual tablets) for adults with fibromyalgia. It is the first new medicine approved for fibromyalgia in more than 15 years. The drug company, Tonix Pharmaceuticals, announced it was available in U.S. pharmacies by prescription on November 17, 2025.
Tonmya dissolves under the tongue and is taken once a day at bedtime. Approval was based on late-stage clinical trials. In the RESILIENT trial, people taking Tonmya had less daily pain than those on placebo after 14 weeks.
What it means for you now: Tonmya is a new option to ask your doctor about, especially if pain and poor sleep are both problems. It joins pregabalin, duloxetine, and milnacipran as FDA-approved choices.
Honest caution: It is not for everyone. The label says it should not be used with MAO inhibitor medicines (or within 14 days of stopping one), after a recent heart attack, or with heart rhythm problems, heart block, heart failure, or an overactive thyroid. Common side effects include numbness or tingling in the mouth and drowsiness. It may harm a developing baby early in pregnancy, so a pregnancy test and birth control are advised for those who could become pregnant. Cost and insurance coverage can also be a hurdle with a new brand-name drug.
2. Stanza: A Prescription App for Fibromyalgia
What it is: Stanza is a smartphone app that teaches acceptance and commitment therapy (ACT), a type of talk therapy that helps you live by your values while learning new ways to respond to pain. In May 2023, the FDA granted it De Novo authorization, making it the first digital therapy for fibromyalgia symptoms.
The main trial, called PROSPER-FM, was published in The Lancet in 2024. It included 275 adults. After 12 weeks, 71 percent of people using the app said their overall condition had improved, compared with 22 percent in a group using a symptom-tracking app.
Where it stands in 2026: In February 2025, the insurer Highmark began covering Stanza. In July 2026, the health company XRHealth announced it had acquired Swing Therapeutics, the maker of Stanza. Stanza still requires a prescription, and whether you can get it depends on where you live and your insurance.
What it means for you now: If you cannot easily reach a pain psychologist, a prescription app may be a practical way to get ACT skills at home. Ask your doctor whether it is offered where you live.
Honest caution: The trial was funded by the company, and the comparison group used a tracking app rather than another active therapy. Access is limited by state and insurance, and you need a smartphone and some daily time to use it.
3. Small Fiber Nerve Findings
What it is: Small fibers are tiny nerves in the skin that carry pain and temperature signals. A 2019 review in Seminars in Arthritis and Rheumatism pooled eight studies and found signs of small fiber damage in about 49 percent of people with fibromyalgia. Tests used included skin biopsies and eye scans.
What it means for you now: This research helps show that fibromyalgia has physical roots. If you have burning, tingling, or numb feet or hands, it is reasonable to ask your doctor whether testing for small fiber neuropathy makes sense for you, since some causes can be treated.
Honest caution: The review was small, with just over 200 people in total, and the authors said the link between small fiber changes and pain is still unclear. Many people with fibromyalgia do not have these findings. It is not yet a test everyone with fibromyalgia needs.
4. Immune and Antibody Studies
What it is: In 2021, researchers published a study in The Journal of Clinical Investigation that drew a lot of attention. They took antibodies (a type of immune protein called IgG) from people with fibromyalgia and injected them into mice. The mice became more sensitive to pressure and cold and had weaker grip strength. Antibodies from healthy people did not do this. The symptoms faded as the antibodies cleared from the mice’s bodies.
What it means for you now: This study suggests the immune system may play a part in fibromyalgia for at least some people. It adds to evidence that fibromyalgia is a real, physical condition.
Honest caution: This was a study in mice. It has not led to any approved test or treatment. Ideas like filtering antibodies out of the blood would need careful human trials first. Be wary of anyone offering costly “immune” treatments for fibromyalgia based on this work.
5. The Nociplastic Pain Framework
What it is: Doctors used to describe pain in two main ways: pain from tissue damage, like a sprained ankle, and pain from nerve damage. The International Association for the Study of Pain added a third type, called nociplastic pain, in 2017, and a major 2021 review in The Lancet helped bring it into wider use. This is pain that comes from changes in how the nervous system processes pain signals. Fibromyalgia is a leading example. Brain imaging and other studies have helped shape this idea.
What it means for you now: This framework gives doctors clear words for pain that is real even when scans and blood tests look normal. It also explains why treatments aimed at the nervous system, like exercise, sleep care, and certain medicines, tend to help more than anti-inflammatory drugs, opioids, injections, or surgery.
Honest caution: The exact causes of nociplastic pain are still not fully understood, and there is no single test for it yet.
6. New Drug Ideas Still in Testing
What it is: A study in the May 2026 issue of the journal PAIN, from the University of Utah, supported a rat model for fibromyalgia research. In those rats, the diabetes drug metformin and exposure to green light reduced fibromyalgia-like symptoms. A human trial of metformin for fibromyalgia is recruiting.
A June 2026 research review in Clinical and Experimental Rheumatology also noted early studies of other approaches, including psilocybin, cannabinoids, and nerve stimulation methods such as vagus nerve stimulation.
What it means for you now: Researchers are testing more ideas than ever. If you are interested in helping, you can search for fibromyalgia studies at ClinicalTrials.gov and talk with your doctor.
Honest caution: Animal results often do not carry over to people. Do not start metformin or any other drug for fibromyalgia on your own. These remain experimental until human trials show they are safe and helpful.
7. Low-Dose Naltrexone: Still Mixed
What it is: Low-dose naltrexone (LDN) is an off-label option some doctors prescribe. A 2023 randomized trial of 99 women in Denmark found it did not lower pain more than placebo. A 12-month trial of 98 women in Spain, published in 2026, also found no clear benefit. Reviews published in 2025 and 2026 disagree on whether it offers a small benefit.
What it means for you now: LDN is not a proven treatment. If you are curious, discuss it with your doctor.
Honest caution: LDN is not safe for anyone who takes opioid pain medicine.
What Has Not Changed
Even with all this news, the basics still have the strongest support. EULAR’s 2016 guidelines gave exercise the only “strong” recommendation of any fibromyalgia treatment. Gentle, steady movement, good sleep habits, pacing, and talk therapies like CBT remain the foundation. New treatments are best seen as add-ons to that base.
Frequently Asked Questions
Is there a cure for fibromyalgia in 2026?
No. There is still no cure. But there are more treatment options than a few years ago, including a new FDA-approved medicine and a prescription therapy app.
What is the newest fibromyalgia medication?
Tonmya, a form of cyclobenzaprine that dissolves under the tongue at bedtime, was approved by the FDA in August 2025. It became available in U.S. pharmacies in November 2025. Ask your doctor whether it is safe for you.
Is fibromyalgia an autoimmune disease?
Not according to current evidence. A 2021 study in mice suggested antibodies may play a role in some people, but this is early research. Fibromyalgia is not classified as an autoimmune disease.
How can I join a fibromyalgia study?
You can search ClinicalTrials.gov for fibromyalgia studies near you. Talk with your doctor before joining, and make sure you understand what the study involves.
The Bottom Line
Fibromyalgia research is moving forward, with a new medicine, a prescription therapy app, and growing evidence that the condition has real physical roots. Some findings, like the antibody and animal studies, are still early and are not ready for everyday care. Exercise, sleep care, pacing, and talk therapy remain the foundation. Bring any new option to your doctor so you can decide together if it fits your health and goals.
Sources
- FDA approves Tonmya for fibromyalgia treatment (Healio, Aug. 15, 2025)
- Tonix Pharmaceuticals Form 8-K: Tonmya commercially available (SEC, Nov. 17, 2025)
- Self-guided digital behavioral therapy improved fibromyalgia management, pain (Rheumatology Live, Sept. 2024)
- A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia (Seminars in Arthritis and Rheumatism, 2019)
- Passive transfer of fibromyalgia symptoms from patients to mice (Journal of Clinical Investigation, 2021; IASP summary)
- Nociplastic pain: towards an understanding of prevalent pain conditions (The Lancet, 2021)
New from Anna Curran, RN
Fibromyalgia: A Nurse’s Guide to Less Pain, Better Sleep and More Good Days
A plain-language guide to medicines, pacing, sleep, gentle movement, flares, work and family life, with trackers and planners. Paperback, hardcover and Kindle.
This article is for general education only and is not medical advice. Talk with your own doctor or licensed provider before you start, stop or change any treatment. In an emergency, call 911. In crisis, call or text 988. See our medical disclaimer.